News

Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. That's because they have been partnering to develop a

Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the

Pfizer's (NYSE: PFE) stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent

Are you a pro when it comes to procrastination? Some investors take so long to make a decision on buying stocks that they miss out on great upside moves. And when those stocks pay juicy dividends

Some investors intend to hold shares of the companies they own for good, never having to sell them. This strategy makes sense. Warren Buffett, the man widely regarded as the greatest contemporary

If you want an investment to make you a millionaire, you need three things. The first is some decent money to invest in the stock market, ideally at least $20,000. The second is time and patience --

Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and

All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting

When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity

Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.

There's a good reason for this

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader

AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while

Both Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) can claim to investors that plenty more growth is on the way. With new markets beckoning and multi-year strategic plans in full swing, both of

Almost like clockwork, Halloween ended, stores started setting up for the all-important holiday shopping season, and the stock market started what could potentially end up as one heck of an early

You've probably heard all the old expressions about acting too quickly. "Haste makes waste" and "Look before you leap" are two that readily come to mind. However, there's also danger in waiting too

It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's

The average stock in the S&P 500 has a dividend that only yields 1.6%. However, investors can secure much higher yields than that without taking on much extra risk. If you've got $5,000 that you can

It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought

Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter

Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q3 2023 Earnings CallNov 08, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this

Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its

Image source: The Motley Fool.

Vertex Pharmaceuticals (NASDAQ: VRTX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com